Exelixis, Inc. - Common Stock (EXEL)
44.46
+7.51 (20.31%)
NASDAQ · Last Trade: May 14th, 1:58 PM EDT
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Via Benzinga · May 14, 2025
The top-notch biotech company easily beat first-quarter profit expectations.
Via Investor's Business Daily · May 13, 2025
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
Via Chartmill · May 1, 2025

A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article.
Via Chartmill · March 10, 2025
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 28, 2025
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
Via Chartmill · April 25, 2025
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL).
Via Chartmill · April 16, 2025
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout.
Via Chartmill · April 14, 2025
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing.
Via Chartmill · April 5, 2025
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Via Chartmill · April 3, 2025
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.
Via Benzinga · March 26, 2025
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill · March 22, 2025
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · March 13, 2025

Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally.
Via Talk Markets · March 12, 2025